GSK Stock ( NYSE:GSK )
The American Depository Shares of GSK ( NYSE:GSK ) dropped by almost 2% in pre-market trading on Wednesday after a story from Bloomberg Businessweek alleged that the British pharmaceutical giant had chosen to remain silent about the cancer risks associated with the recalled heartburn treatment Zantac. As a result, GSK stock declined in the market.
Concerns over the possible carcinogenic effects of N-nitroso dimethylamine (NDMA) led to the withdrawal of Zantac, commonly known as ranitidine, from the U.S. market in 2020.
Since then, hundreds of lawsuits have been filed against the companies that produce generic versions of Zantac, including Sanofi (OTCPK:SNYNF), GlaxoSmithKline, Pfizer, and Boehringer Ingelheim GmbH.
Bloomberg cited documents acquired via FOIA requests to support its claim that the FDA examined the cancer risks before approving the treatment, despite GSK stock concealing important trial data.
Even worse, GlaxoSmithKline, as it was then called, funded erroneous research to downplay the seriousness of the situation and decided against standard transit and storage practices that would have mitigated the damage.
When GSK ( NYSE:GSK ) was seeking permission in 1982 for an injectable form of ranitidine, the company’s director of pharmaceutical development, John Padfield, advised that the medicine would need to be kept cold from the time of importation until it was stored in a warehouse.
Padfield warned in March that failing to do so would be “a very seri...
Click here to read the full article on PressReach.com .Subscribe to the PressReach RSS feeds:
- Featured News RSS feed
- Investing News RSS feed
- Daily Press Releases RSS feed
- Trading Tips RSS feed
- Investing Videos RSS feed
Follow PressReach on Twitter
Follow PressReach on TikTok
Follow PressReach on Instagram
Subscribe to us on Youtube